Body Protection Compound 157 (BPC-157) is a pentadecapeptide derived from a protective protein found in gastric juice. Over two decades of preclinical research have established it as one of the most broadly studied repair-promoting peptides in the field, with applications spanning musculoskeletal, gastrointestinal, vascular, and neurological research.
What Is BPC-157?
BPC-157 (Body Protection Compound 157; CAS: 137525-51-0; sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic 15-amino acid peptide originally isolated from human gastric juice. It shares no sequence homology with any known endogenous peptide hormone, yet demonstrates remarkable cytoprotective and regenerative properties across multiple tissue types in preclinical models.
The peptide is stable in gastric acid — an important property that has facilitated oral administration studies in rodent models. It does not bind known receptors in the classical sense; instead, research suggests it modulates nitric oxide (NO) synthesis, growth factor expression (EGF, VEGF, PDGF), and cytoskeletal organization, giving it a uniquely broad mechanism of action.
Tendon and Ligament Healing Research
The most replicated findings in BPC-157 research involve tendon-to-bone healing. Multiple groups have demonstrated that BPC-157 administration in rat Achilles tendon transection models significantly accelerates tendon fiber organization, fibroblast proliferation, and collagen synthesis. Histological analyses show improved cross-link density and superior tensile strength in treated tendons at 2 and 4 weeks post-injury.
A particularly notable observation is the upregulation of tendon-specific growth factors, including Tenascin-C and type I collagen mRNA, in BPC-157-treated fibroblast cultures. In vivo medial collateral ligament (MCL) repair models have shown earlier restoration of functional biomechanical properties with BPC-157 versus control groups.
- Accelerated Achilles tendon repair in transection models (multiple independent replications)
- Increased type I and III collagen deposition in healing tissue
- Upregulation of VEGF and EGF receptor expression in fibroblasts
- Improved biomechanical strength at 14-day endpoints in MCL repair studies
- Reduction of inflammatory cell infiltration in early healing phase
Gastrointestinal Research
BPC-157 was originally identified in the context of gastrointestinal cytoprotection. Research has consistently demonstrated its protective effects in rodent models of ulcer induction (NSAID-induced, ethanol-induced, and acetic acid-induced). At nanomolar to micromolar concentrations, it reverses mucosal damage, restores goblet cell density, and normalizes inflammatory cytokine profiles in colonic tissue.
In IBD research, BPC-157 has been studied in trinitrobenzene sulfonic acid (TNBS) and dextran sodium sulfate (DSS) models of colitis. Animals receiving BPC-157 show significantly reduced colon weight/length ratios (a marker of edema and shortening), lower myeloperoxidase activity, and improved histological scores. The peptide appears to act on EGF receptor signaling pathways within the intestinal epithelium.
Research has also explored the gut-brain axis effects of BPC-157, demonstrating normalization of dopaminergic and serotonergic activity in the mesolimbic system following peripheral BPC-157 administration — a finding with implications for gut motility and mood-related research.
Angiogenesis and Vascular Research
One of the most significant mechanistic contributions of BPC-157 research is the demonstration of its potent pro-angiogenic activity. Studies in Matrigel plug assays, chorioallantoic membrane (CAM) models, and tube formation assays with human umbilical vein endothelial cells (HUVECs) show that BPC-157 robustly stimulates new blood vessel formation.
The mechanism appears to involve upregulation of VEGF expression and activation of VEGFR2 downstream signaling (PI3K/Akt and MAPK/ERK pathways). BPC-157 has also been shown to promote eNOS (endothelial nitric oxide synthase) activity, increasing NO-mediated vasodilation and reducing ischemic injury in hind-limb ischemia models.
| Research Area | Model Used | Primary Endpoint | Result |
|---|---|---|---|
| Tendon healing | Rat Achilles transection | Tendon fiber organization | Significantly improved vs control |
| GI protection | NSAID-induced ulcer (rat) | Ulcer index score | 70–80% reduction |
| Angiogenesis | HUVEC tube formation | Tube length/junctions | 2–3× increase |
| Neurological | MPTP mouse model | Dopaminergic neuron count | Partial preservation |
| Muscle injury | Crush injury model | Muscle weight recovery | Accelerated by ~30% |
Neurological and Cognitive Research
Preclinical research has explored BPC-157 in models of traumatic brain injury, stroke, and neurodegeneration. In focal cerebral ischemia models, BPC-157 reduces infarct volume, improves neurological deficit scores, and preserves brain-blood barrier integrity as measured by Evans blue extravasation. The proposed mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and activation of the mTOR pathway.
In models of spinal cord injury, BPC-157 administration significantly improves motor function recovery at 4- and 8-week endpoints, and histological analysis shows reduced cavitation, improved axonal sparing, and increased Schwann cell migration. These neurological findings represent one of the most exciting frontiers in BPC-157 research.
Research Dosing and Stability Notes
In preclinical rodent research, BPC-157 is typically studied at doses ranging from 1 µg/kg to 10 µg/kg administered intraperitoneally, subcutaneously, or orally. The peptide demonstrates dose-dependent effects in some models but appears remarkably effective even at very low concentrations in others, suggesting high receptor sensitivity or receptor-independent mechanisms.
Research-grade BPC-157 should be stored at −20°C in lyophilized form and used within 24 hours of reconstitution for maximal biological activity. HPLC purity of ≥98% is required for reliable bioassay results.
Conclusion
The breadth of BPC-157's demonstrated preclinical effects — spanning connective tissue repair, gastrointestinal protection, angiogenesis, and neuroprotection — makes it one of the most compelling research peptides available. Its lack of known toxicity at research doses in rodent models, combined with stability in biological fluids, makes it a practical tool for multi-system research.
Further elucidation of its receptor interactions and downstream signaling cascades remains an active area of investigation. Researchers at Peak Peptides Solutions USA Sales can access high-purity BPC-157 for qualified in vitro and preclinical research applications.
Research Use Only
All information in this article is provided for educational and informational purposes only. This content does not constitute medical advice. Products referenced are for in vitro scientific research only and are not intended for human consumption, clinical use, or self-administration. Always consult qualified research professionals.